The "Defending Affordable Prescription Drug Costs Act" seeks to protect 340B entities and the drugs they provide by prohibiting discriminatory practices from drug manufacturers, health insurance issuers, and pharmacy benefit managers. The bill introduces new sections in Florida Statutes that define 340B drugs and entities, ensuring that these entities are treated equitably compared to non-340B entities. It specifically prohibits practices that restrict or interfere with the acquisition and reimbursement of 340B drugs, including imposing additional requirements or restrictions that create unnecessary burdens on 340B entities.

Violations of these provisions will be classified as deceptive and unfair trade practices under the Florida Deceptive and Unfair Trade Practices Act, subjecting violators to penalties. The bill also clarifies that it does not conflict with federal laws and maintains that limited distribution of certain drugs under risk evaluation and mitigation strategies is not a violation. The legislation aims to ensure that patients can access their medications from 340B entities without facing additional charges or restrictions, promoting equitable access to necessary drugs. The bill is set to take effect on July 1, 2026.